Leukemia and Lymphoma

Novartis Says Tisagenlecleucel Met CRR in Early FL Data

August 05, 2020

Article

Tisagenlecleucel, sold as Kymriah by Novartis, met its primary end point of complete response rate (CRR) in an interim analysis of a phase 2 study for relapsed or refractory follicular lymphoma (FL).

Tafasitamab Combination Approved for Adults With R/R DLBCL

August 02, 2020

Article

A new treatment option is approved for patients with a common form of non-Hodgkin lymphoma who cannot have an autologous stem cell transplant.

In Assessing CLL HRQoL, Type of Questionnaire Matters, Study Says

July 31, 2020

Article

Understanding the patient point of view can help with treatment decisions as well as gauge the impact of treatment, the authors said.

Immunoglobulin Abnormalities Do Not Affect Overall Survival in CLL, Study Finds

July 31, 2020

Article

While immunoglobulin abnormalities appear to shorten treatment-free survival periods, they do not have an impact on overall survival in patients with chronic lymphocytic leukemia (CLL).

FDA Approves CAR T-Cell Therapy for Adults With R/R Mantle Cell Lymphoma

July 25, 2020

Article

The therapy, to be sold as Tecartus, will be used to treat adult patients with mantle cell lymphoma who have relapsed or not responded to other treatments.

CLL Experts Favor Social Distancing, but Vary on Treatment Continuation Amid Pandemic

July 24, 2020

Article

Experts surveyed regarding how best to treat patients with chronic lymphocytic leukemia (CLL) amid the pandemic agreed with social distancing, but were cautious about universal testing and treatment continuation.

Age, Recent Treatment Appear to Influence Severity of COVID-19 in Patients With CLL

July 18, 2020

Article

Older patients with chronic lymphocytic leukemia (CLL) appear to be more likely to have severe symptoms if they contract coronavirus disease 2019, according to new research.

Leukemia Rates Falling, but AML, CLL Are Exceptions

July 18, 2020

Article

A new analysis of nearly 3 decades of data suggests leukemia rates are falling, except for 2 specific types.

FDA Lifts Partial Hold for Phase 2 Trial of R/R Hodgkin Lymphoma Therapy

July 08, 2020

Article

FDA has lifted a partial clinical hold on a phase 2 trial of a treatment for patients with relapsed or refractory (R/R) Hodgkin lymphoma from ADC Therapeutics. The trial of camidanlumab tesirine (Cami), an antibody drug conjugate that binds to CD25, is evaluating the safety and efficacy of the therapy and is intended to support the submission of a Biologics License Application to the FDA.

NCCN Patient Guidelines Highlight Side Effects of Immunotherapy, CAR T-Cell Therapy

July 03, 2020

Article

Immunotherapy and chimeric antigen receptor (CAR) T-cell therapy are new and important treatments revolutionizing care of some cancers; however, their side effects can be very different than what is seen in traditional approaches, such as chemotherapy.